N-(2-羟基苯基)-2-甲基丙酰胺 | 105294-80-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-(2-羟基苯基)-2-甲基丙酰胺
• 中文别名: 丙酰胺,N-(2-羟基苯基)-2-甲基-
• 英文名称: N-(2-hydroxyphenyl)isobutyramide
• 英文别名: N-(2-hydroxyphenyl)-2-methylpropanamide
• CAS: 105294-80-2
• 化学式: C₁₀H₁₃NO₂
• mdl: MFCD00462962
• 分子量: 179.219
• InChiKey: HFHKGYSSGAHTMV-UHFFFAOYSA-N

物化性质

• 沸点：
  351.1±25.0 °C(Predicted)
• 密度：
  1.161±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-(2-羟基苯基)-2-甲基丙酰胺 、 1-萘甲酰氯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 [2-(2-Methylpropanoylamino)phenyl] naphthalene-1-carboxylate
  参考文献：
  名称：

  N,O-二酰基-o-氨基苯酚的叔胺催化的酰基交换反应。决定酰基交换异构体相对稳定性的机制和因素

  摘要：

  已经在不同极性的溶剂中研究了酰基取代基对各种 N,O-二酰基-o-氨基苯酚的酰基交换反应的平衡和速率常数的影响。发现酰基交换的异构体对的相对稳定性仅由酰基的诱导作用决定，条件是与酰胺氮键合的酰基取代基的空间位阻对稳定性产生相同程度的影响。通过分析标准自由能变化 (ΔG°) 和 pKa 之间的相关性，证明了由庞大的酰基施加的空间位阻在确定相对稳定性方面的重要性，标准自由能变化 (ΔG°) 和 pKa 用作异构体对的相对稳定性的量度和分别为酰基的吸电子能力。另一方面，酰基迁移反应的催化速率常数的对数与 pKa 值密切相关。除了这个发现之外，激活熵的大负值 ΔS\eweq=...

  DOI：

  10.1246/bcsj.63.3141
• 作为产物：
  描述：

  2-isobutyramidophenyl isobutyrate 在 potassium hydroxide 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 以55.5%的产率得到N-(2-羟基苯基)-2-甲基丙酰胺
  参考文献：
  名称：

  Discovery of new low-molecular-weight p53–Mdmx disruptors and their anti-cancer activities

  摘要：

  Although several p53-Mdm2-binding disruptors have been identified to date, few studies have been published on p53-Mdmx-interaction inhibitors. In the present study, we demonstrated that o-aminothiophenol derivatives with molecular weights of 200-300 selectively inhibited the p53-Mdmx interaction. S-2-Isobutyramidophenyl 2-methylpropanethioate (K-178) (1c) activated p53, up-regulated the expression of its downstream genes such as p21 and Mdm2, and preferentially inhibited the growth of cancer cells with wild-type p53 over those with mutant p53. Furthermore, we found that the S-isobutyryl-deprotected forms 1b and 3b of 1c and S-2-benzamidophenyl 2-methylpropanethioate (K-181) (3c) preferentially inhibited the p53-Mdmx interaction over the p53-Mdm2 interaction, respectively, by using a Flag-p53 and glutathione S-transferase (GST)-fused protein complex (Mdm2, Mdmx, DAPK1, or PPID). In addition, the interaction of p53 with Mdmx was lost by replacing a sulfur atom with an oxygen atom in 1b and 1c. These results suggest that sulfides such as 1b, 3b, 4b, and 5b interfere with the binding of p53-Mdmx, resulting in the dissociation of the two proteins. Furthermore, the results of oral administration experiments using xenografts in nude mice indicated that 1c reduced the volume of tumor masses to 49.0% and 36.6% that of the control at 100 mg/kg and 150 mg/kg, respectively, in 40 days. (C) 2016 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2016.03.021

文献信息

• "MULTI-TARGET" COMPOUNDS WITH INHIBITORY ACTIVITY TOWARDS HISTONE DEACETYLASES AND TUBULIN POLYMERISATION, FOR USE IN THE TREATMENT OF CANCER
  申请人：UNIVERSITE PARIS-SUD

  公开号：US20190023645A1

  公开（公告）日：2019-01-24

  The present invention relates to the design of novel molecules, referred to as “multi-target” molecules, having a double pharmacophore and acting both as inhibitors of histone deacetylases (HDACs) and as inhibitors of tubulin polymerisation. The invention also describes the method for synthesising the “multi-target” molecules and their use in the treatment of cancer, a pharmaceutical composition comprising at least one “multi-target” molecule, and the use of such compositions in the treatment of cancer.

  本发明涉及新型分子的设计，被称为“多靶点”分子，具有双药效团，既作为组蛋白去乙酰化酶（HDACs）的抑制剂，又作为微管聚合的抑制剂。该发明还描述了合成“多靶点”分子的方法及其在癌症治疗中的应用，包括至少一种“多靶点”分子的药物组合物，以及这些组合物在癌症治疗中的应用。
• HISTONE DEACETYLASE INHIBITORS
  申请人：Bradner James Elliot

  公开号：US20100056588A1

  公开（公告）日：2010-03-04

  In recognition of the need to develop novel therapeutic agents, the present invention provides novel histone deacetylase inhibitors. These compounds include an ester bond making them sensitive to deactivation by esterases. Therefore, these compounds are particularly useful in the treatment of skin disorders. When the compounds reaches the bloodstream, an esterase or an enzyme with esterase activity cleaves the compound into biologically inactive fragments or fragments with greatly reduced activity Ideally these degradation products exhibit a short serum and/or systemic half-life and are eliminated rapidly. These compounds and pharmaceutical compositions thereof are particularly useful in treating cutaneous T-cell lymphoma, neurofibromatosis, psoriasis, hair loss, skin pigmentation, and dermatitis, for example. The present invention also provides methods for preparing compounds of the invention and intermediates thereto.

  为了开发新型治疗剂，本发明提供了新型组蛋白去乙酰化酶抑制剂。这些化合物包括酯键，使它们对酯酶的失活敏感。因此，这些化合物在治疗皮肤疾病方面特别有用。当这些化合物进入血液循环时，酯酶或具有酯酶活性的酶将其裂解成生物学上不活性的碎片或具有大大降低活性的碎片。理想情况下，这些降解产物表现出短的血清和/或系统半衰期，并迅速被排出体外。这些化合物及其制剂在治疗切除性T细胞淋巴瘤、神经纤维瘤、银屑病、脱发、皮肤色素沉着和皮炎等方面特别有用。本发明还提供了制备本发明化合物及其中间体的方法。
• Hydrogen barrier agent, hydrogen barrier film forming composition, hydrogen barrier film, method for producing hydrogen barrier film, and electronic element
  申请人：TOKYO OHKA KOGYO CO., LTD.

  公开号：US10023540B2

  公开（公告）日：2018-07-17

  To provide a hydrogen barrier agent capable of imparting hydrogen barrier performance to various materials; a hydrogen barrier film forming composition including the hydrogen barrier agent; a hydrogen barrier film including the hydrogen barrier agent; a method for producing a hydrogen barrier film, which uses the hydrogen barrier film forming composition; and an electronic element provided with the hydrogen barrier film. A compound having a specific structure including an imidazolyl group is used as the hydrogen barrier agent. Furthermore, the hydrogen barrier film forming composition is prepared by blending the above-mentioned hydrogen barrier agent into the base material component. In addition, the hydrogen barrier film is formed using the hydrogen barrier film forming composition.

  提供一种能使各种材料具有氢阻隔性能的氢阻隔剂；一种包括该氢阻隔剂的氢阻隔薄膜形成组合物；一种包括该氢阻隔剂的氢阻隔薄膜；一种使用该氢阻隔薄膜形成组合物生产氢阻隔薄膜的方法；以及一种带有该氢阻隔薄膜的电子元件。氢阻隔剂使用了一种具有特定结构的化合物，其中包括咪唑基团。此外，氢阻隔膜形成组合物是通过将上述氢阻隔剂与基础材料成分混合而制备的。此外，使用氢阻隔膜形成组合物形成氢阻隔膜。
• Histone deacetylase inhibitors
  申请人：President & Fellows of Harvard College

  公开号：US10172821B2

  公开（公告）日：2019-01-08

  In recognition of the need to develop novel therapeutic agents, the present invention provides novel histone deacetylase inhibitors. These compounds include an ester bond making them sensitive to deactivation by esterases. Therefore, these compounds are particularly useful in the treatment of skin disorders. When the compounds reaches the bloodstream, an esterase or an enzyme with esterase activity cleaves the compound into biologically inactive fragments or fragments with greatly reduced activity Ideally these degradation products exhibit a short serum and/or systemic half-life and are eliminated rapidly. These compounds and pharmaceutical compositions thereof are particularly useful in treating cutaneous T-cell lymphoma, neurofibromatosis, psoriasis, hair loss, skin pigmentation, and dermatitis, for example. The present invention also provides methods for preparing compounds of the invention and intermediates thereto.

  考虑到开发新型治疗药物的需要，本发明提供了新型组蛋白去乙酰化酶抑制剂。这些化合物包括一个酯键，使其对酯酶的失活敏感。因此，这些化合物特别适用于治疗皮肤疾病。当这些化合物进入血液后，酯酶或具有酯酶活性的酶会将化合物裂解为无生物活性的片段或活性大大降低的片段，理想情况下，这些降解产物的血清和/或全身半衰期很短，并能迅速消除。这些化合物及其药物组合物尤其适用于治疗皮肤 T 细胞淋巴瘤、神经纤维瘤病、银屑病、脱发、皮肤色素沉着和皮炎等。本发明还提供了制备本发明化合物及其中间体的方法。
• Treatment of protein degradation disorders
  申请人：President and Fellows of Harvard College

  公开号：US10172905B1

  公开（公告）日：2019-01-08

  The invention relates to methods of treating protein degradation disorders, such cellular proliferative disorders (e.g., cancer) and protein deposition disorders (e.g., neurodegenerative disorders). The invention provides methods and pharmaceutical compositions for treating these diseases using aggresome inhibitors or combinations of aggresome inhibitors and proteasome inhibitors. The invention further relates to methods and pharmaceutical compositions for treating multiple myeloma. New HDAC/TDAC inhibitors and aggresome inhibitors are also provided as well as synthetic methodologies for preparing these compounds.

  本发明涉及治疗蛋白质降解紊乱的方法，如细胞增殖紊乱（如癌症）和蛋白质沉积紊乱（如神经退行性疾病）。本发明提供了使用侵袭酶体抑制剂或侵袭酶体抑制剂和蛋白酶体抑制剂组合治疗这些疾病的方法和药物组合物。本发明还涉及治疗多发性骨髓瘤的方法和药物组合物。本发明还提供了新的 HDAC/TDAC 抑制剂和侵袭体抑制剂以及制备这些化合物的合成方法。